Regeneron Pharmaceuticals Inc (REGN)

NASDAQ
Currency in USD
Disclaimer
736.58
+1.02
(+0.14%)
Real-time Data
Day's Range
729.02
738.84
52 wk Range
538.01
837.55
Volume
125,956
Prev. Close
735.56
Open
736
Day's Range
729.02-738.84
52 wk Range
538.01-837.55
Volume
125,956
Average Volume (3m)
572,425
1-Year Change
10.65%
Shares Outstanding
107,110,254
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
883.78
Upside +19.83%

People Also Watch

87.63
CPRT
+0.05%
44.79
SLB
+4.58%
315.40
0700
+1.55%
1,552.60
ADYEN
+1.69%

Regeneron Pharmaceuticals Inc News

Regeneron Pharmaceuticals Inc Analysis

Regeneron Pharmaceuticals Inc Company Profile

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.